Exploring a combined biomarker for tuberculosis treatment response: protocol for a prospective observational cohort study. Issue 7 (8th July 2021)

• Record Type: Journal Article
• Authors: Kloprogge, Frank; Abubakar, Ibrahim; Esmail, Hanif; Hack, Vanessa; Kunst, Heinke; McHugh, Timothy D; Noursadeghi, Mahdad; Surey, Julian; Tiberi, Simon; Lipman, Marc
• Is Part Of: BMJ open. Volume 11:Issue 7(2021)
• Publication Date: 2021-07-08
• Subjects: tuberculosis -- bacteriology -- clinical pharmacology; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-052885
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: An improved understanding of factors explaining tuberculosis (TB) treatment response is urgently needed to help clinicians optimise and personalise treatment and assist scientists undertaking novel treatment regimen trials. Promising outcome proxy measures, including sputum bacillary load and host immune response, are widely reported with variable results. However, they have not been studied together in combination with antibiotic exposure. The aim of this observational cohort study is to investigate which antibiotic exposures correlate with sputum bacillary load and which with the host immune response. Subsequently, we will explore if these correlations can be used to inform a candidate combined biomarker predicting cure. Methods and analysis: All patients aged ≥ 18, diagnosed with drug-sensitive pulmonary TB (culture or molecular test), eligible for standard anti-TB treatment, at selected London, UK TB Services, will be invited to participate in this observational cohort study (target sample size=210). Patients will be asked to give blood for host transcriptomics and antibiotic plasma exposure, in addition to standard of care sputum samples for bacillary load. Antibiotic plasma concentrations will be quantified using a validated liquid chromatograph triple quadrupole mass spectrometer (LC-MS/MS) assay and sputum bacillary load by mycobacterial growth incubator tube time to positivity. Expression from a total of 35 prespecified host blood genes will be quantified using NanoString®. Antibiotic exposure, sputum bacillary load and host blood transcriptomic time series data will be analysed using nonlinear mixed-effects models. Correlations between combinations of longitudinal biomarkers and microbiological cure at the end of treatment and remaining relapse free for 1 year thereafter will be analysed using logistic regression and Cox proportional hazard models. Ethics and dissemination: The observational cohort study has been approved by the UK's HRA REC (20/SW/0007). Written informed consent will be obtained. Results will be disseminated via publication, presentation and through engagement with institutes/companies developing novel anti-TB treatment combinations.